Previous studies demonstrated that weight loss achieved by administration of SGLT2 inhibitors or short-term hospitalization with calorie restriction can reduce serum sDPP-4/CD26 in people with type 2 diabetes and MASLD.21 The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.